Akari Therapeutics, Plc (AKTX)

Market Cap	22.33M +4.5%
Revenue (ttm)	n/a
Net Income	-30.96M
EPS	-23.94
Shares Out	1.95M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	108,637
Open	10.41
Previous Close	10.84
Day's Range	10.17 - 11.82
52-Week Range	3.02 - 49.60
Beta	1.43
Analysts	Buy
Price Target	28.50 (+148.47%)
Earnings Date	Aug 13, 2026

About AKTX

Akari Therapeutics, Plc, an oncology company, develops antibody-drug conjugates (ADC) for cancer-killing toxins. Its lead payload is PH1 to disrupt the function of spliceosomes and to trigger an immune response that leads to additional cancer cell killing. The company’s lead product candidate is AKTX-101, a preclinical stage trop2-targeting ADC that combines PH1 with the trop2 antibody to treat solid tumor cancer types, including lung, breast, bladder, head and neck, gastric, pancreatic, colon, prostate, and others. Its payloads include PH1 is ...

• Industry: Biotechnology
• Sector: Healthcare
• CEO: Abizer Gaslightwala
• Employees: 6
• Stock Exchange: NASDAQ
• Ticker Symbol: AKTX
• Website: https://www.akaritx.com

Analyst Summary

According to 2 analysts, the average rating for AKTX stock is "Buy." The 12-month stock price target is $28.5, which is an increase of 148.47% from the latest price.

Price Target

$28.5

(148.47% upside)

Analyst Consensus: Buy

Data Sources: S&P Global Market Intelligence, CBOE, and more

Fundamental and historical data is provided by S&P Global Market Intelligence. Real-time stock price data is provided by CBOE and 15-minute delayed consolidated tape pricing data is provided by Nasdaq UTP.

Last checked:

Sep 5, 2026

Data Sources Report a data error